Variation in Mycobacterium tuberculosis population structure in Iran: a systemic review and meta-analysis.

Genetic Variation Genotype Humans Iran / epidemiology Mycobacterium tuberculosis / genetics Prevalence Tuberculosis, Pulmonary / epidemiology
Diversity Genotype Iran Meta-analysis Mycobacterium tuberculosis

Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
04 Jan 2021
Historique:
received: 03 07 2020
accepted: 19 11 2020
entrez: 5 1 2021
pubmed: 6 1 2021
medline: 20 1 2021
Statut: epublish

Résumé

Acquiring comprehensive insight into the dynamics of Mycobacterium tuberculosis (Mtb) population structure is an essential step to adopt effective tuberculosis (TB) control strategies and improve therapeutic methods and vaccines. Accordingly, we performed this systematic review and meta-analysis to determine the overall prevalence of Mtb genotypes/ sublineages in Iran. We carried out a comprehensive literature search using the international databases of MEDLINE and Scopus as well as Iranian databases. Articles published until April 2020 were selected based on the PRISMA flow diagram. The overall prevalence of the Mtb genotypes/sublineage in Iran was determined using the random effects or fixed effect model. The metafor R package and MedCalc software were employed for performing this meta-analysis. We identified 34 studies for inclusion in this study, containing 8329 clinical samples. Based on the pooled prevalence of the Mtb genotypes, NEW1 (21.94, 95% CI: 16.41-28.05%), CAS (19.21, 95% CI: 14.95-23.86%), EAI (12.95, 95% CI: 7.58-19.47%), and T (12.16, 95% CI: 9.18-15.50%) were characterized as the dominant circulating genotypes in Iran. West African (L 5/6), Cameroon, TUR and H37Rv were identified as genotypes with the lowest prevalence in Iran (< 2%). The highest pooled prevalence rates of multidrug-resistant strains were related to Beijing (2.52, 95% CI) and CAS (1.21, 95% CI). This systematic review showed that Mtb populations are genetically diverse in Iran, and further studies are needed to gain a better insight into the national diversity of Mtb populations and their drug resistance pattern.

Sections du résumé

BACKGROUND BACKGROUND
Acquiring comprehensive insight into the dynamics of Mycobacterium tuberculosis (Mtb) population structure is an essential step to adopt effective tuberculosis (TB) control strategies and improve therapeutic methods and vaccines. Accordingly, we performed this systematic review and meta-analysis to determine the overall prevalence of Mtb genotypes/ sublineages in Iran.
METHODS METHODS
We carried out a comprehensive literature search using the international databases of MEDLINE and Scopus as well as Iranian databases. Articles published until April 2020 were selected based on the PRISMA flow diagram. The overall prevalence of the Mtb genotypes/sublineage in Iran was determined using the random effects or fixed effect model. The metafor R package and MedCalc software were employed for performing this meta-analysis.
RESULTS RESULTS
We identified 34 studies for inclusion in this study, containing 8329 clinical samples. Based on the pooled prevalence of the Mtb genotypes, NEW1 (21.94, 95% CI: 16.41-28.05%), CAS (19.21, 95% CI: 14.95-23.86%), EAI (12.95, 95% CI: 7.58-19.47%), and T (12.16, 95% CI: 9.18-15.50%) were characterized as the dominant circulating genotypes in Iran. West African (L 5/6), Cameroon, TUR and H37Rv were identified as genotypes with the lowest prevalence in Iran (< 2%). The highest pooled prevalence rates of multidrug-resistant strains were related to Beijing (2.52, 95% CI) and CAS (1.21, 95% CI).
CONCLUSIONS CONCLUSIONS
This systematic review showed that Mtb populations are genetically diverse in Iran, and further studies are needed to gain a better insight into the national diversity of Mtb populations and their drug resistance pattern.

Identifiants

DOI: 10.1186/s12879-020-05639-7 PMID: 33397308 PMC: PMC7784266
pubmed: 33397308
doi: 10.1186/s12879-020-05639-7
pii: 10.1186/s12879-020-05639-7
pmc: PMC7784266
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2

Références

Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30404943
Avicenna J Med Biotechnol. 2010 Jul;2(3):145-52
pubmed: 23408229
Tuberculosis (Edinb). 2018 Sep;112:89-97
pubmed: 30205974
BMC Res Notes. 2018 Jul 17;11(1):486
pubmed: 30016972
Indian J Med Microbiol. 2009 Oct-Dec;27(4):306-10
pubmed: 19736398
Am J Trop Med Hyg. 2014 Jan;90(1):99-105
pubmed: 24189362
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Infect Genet Evol. 2011 Jan;11(1):124-31
pubmed: 20951237
Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S238-S239
pubmed: 28043579
Sci Rep. 2019 Nov 29;9(1):17946
pubmed: 31784605
Stat Med. 2010 Dec 20;29(29):3046-67
pubmed: 20827667
Int J Infect Dis. 2020 Jun;95:22-27
pubmed: 32251801
Mol Phylogenet Evol. 2019 Mar;132:46-52
pubmed: 30513341
Nat Genet. 2013 Oct;45(10):1176-82
pubmed: 23995134
PLoS One. 2019 Jul 12;14(7):e0219706
pubmed: 31299060
BMC Med. 2018 Oct 30;16(1):196
pubmed: 30373589
Mediterr J Hematol Infect Dis. 2014 Feb 16;6(1):e2014015
pubmed: 24678392
Lancet Infect Dis. 2016 Dec;16(12):1326-1327
pubmed: 27998587
Rev Soc Bras Med Trop. 2016 Apr;49(2):204-10
pubmed: 27192590
J Clin Diagn Res. 2014 Sep;8(9):DC05-8
pubmed: 25386431
PLoS One. 2012;7(8):e43170
pubmed: 22916219
Chemotherapy. 2010;56(3):248-57
pubmed: 20551642
Curr Microbiol. 2017 Jan;74(1):14-21
pubmed: 27743106
Infect Genet Evol. 2014 Oct;27:6-14
pubmed: 24981519
Microbiologyopen. 2013 Dec;2(6):988-96
pubmed: 24311556
Nat Commun. 2020 Jun 9;11(1):2917
pubmed: 32518235
Nat Genet. 2016 Dec;48(12):1535-1543
pubmed: 27798628
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
BMC Infect Dis. 2008 Aug 06;8:109
pubmed: 18681980
Infect Dis (Lond). 2019 Sep;51(9):659-667
pubmed: 31314640
Psychol Methods. 2006 Jun;11(2):193-206
pubmed: 16784338
Infect Genet Evol. 2015 Jul;33:1-5
pubmed: 25891279
PLoS Biol. 2008 Dec 16;6(12):e311
pubmed: 19090620
Adv Exp Med Biol. 2017;1019:1-26
pubmed: 29116627
Sci Adv. 2018 Oct 17;4(10):eaat5869
pubmed: 30345355
Tuberculosis (Edinb). 2011 Nov;91(6):510-23
pubmed: 21835699
Braz J Microbiol. 2009 Apr;40(2):314-20
pubmed: 24031364
Int J Bacteriol. 2016;2016:7146470
pubmed: 27819023
J Clin Tuberc Other Mycobact Dis. 2018 Jan 31;11:1-6
pubmed: 31720383
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2869-73
pubmed: 16477032
Mol Phylogenet Evol. 2017 Nov;116:202-212
pubmed: 28893611
J Cell Physiol. 2019 Apr;234(4):4739-4753
pubmed: 30192006
Tuberculosis (Edinb). 2017 Dec;107:31-37
pubmed: 29050769

Auteurs

Shima Hadifar (S)

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Microbiology Research Centre (MRC), Pasteur Institute of Iran, Tehran, Iran.

Abolfazl Fateh (A)

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Microbiology Research Centre (MRC), Pasteur Institute of Iran, Tehran, Iran.

Vahid Pourbarkhordar (V)

Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Science, Isfahan University of Medical Science, Isfahan, Iran.

Seyed Davar Siadat (SD)

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Microbiology Research Centre (MRC), Pasteur Institute of Iran, Tehran, Iran.

Shayan Mostafaei (S)

Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. mostafa.shayan@modares.ac.ir.
Epidemiology and Biostatistics Unit, Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran. mostafa.shayan@modares.ac.ir.

Farzam Vaziri (F)

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran. farzam_vaziri@yahoo.com.
Microbiology Research Centre (MRC), Pasteur Institute of Iran, Tehran, Iran. farzam_vaziri@yahoo.com.
ORCID: 0000-0001-7788-2548

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Variation in Mycobacterium tuberculosis...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Variation in Mycobacterium tuberculosis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Variation in Mycobacterium tuberculosis...
questionsmedicales.fr › Régions géographiques › Asie › Asie de l'Ouest › Moyen Orient › Iran › Variation in Mycobacterium tuberculosis...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Variation in Mycobacterium tuberculosis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Variation in Mycobacterium tuberculosis...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Tuberculose pulmonaire › Variation in Mycobacterium tuberculosis...